is launching a platform for the clinical evaluation of candidate vaccines against Covid-19, called COVIREIVAC. It will allow them to be tested rigorously and to obtain solid data on their ability to induce an immune reaction (immunogenicity) as well as on their safety.
under the direction of I-REIVAC coordinator Odile Launay, professor of infectious and tropical diseases at the University of Paris and coordinator of CIC Cochin Pasteur at Cochin hospital (AP -HP), to test vaccines in rigorous clinical trials, which may include several hundred participants.
We can assume she is well aware of Mymx influenza efforts
Market Data 
Markets 
AI
